Q4 2025 · 13F-HR
Venrock Adviser, LLCholdings as filed
Filed 2026-02-17 · accession 0001615982-26-000005
$2.02B
Reported value
27
Positions
2025-12-31
Period end
The Brief · Venrock Adviser, LLC · Q4 2025
AI · grounded in 13F
Venrock Adviser, LLC closed its position in METSERA INC, reducing exposure by $196.3M. The fund also exited positions in CDTX for $90.7M and ABVX for $49M. On the buy side, the fund established a new position in HELP worth $31.4M and increased its stake in CBIO by 53.7%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $641.1M | 31.7% | 8,493,321 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $125.7M | 6.21% | 4,148,428 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $120.8M | 5.97% | 3,882,709 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $120.7M | 5.96% | 3,685,448 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $108.7M | 5.37% | 6,728,985 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $88.8M | 4.39% | 7,315,547 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $82.9M | 4.09% | 13,740,375 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $71.0M | 3.51% | 2,000,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $66.4M | 3.28% | 17,857,083 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $66.3M | 3.27% | 15,561,500 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $64.2M | 3.17% | 1,548,569 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $49.7M | 2.45% | 3,220,364 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $49.7M | 2.45% | 3,226,331 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $46.4M | 2.29% | 5,676,230 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $43.1M | 2.13% | 4,771,414 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $42.5M | 2.10% | 2,173,913 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $41.2M | 2.04% | 1,000,000 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $31.7M | 1.57% | 1,169,298 | Common | SOLE |
| 23256X407 | HELP | CYBIN INC | $31.4M | 1.55% | 3,840,250 | Common | SOLE |
| G9TY5A101 | ZURA | ZURA BIO LTD | $28.0M | 1.38% | 5,345,115 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $25.4M | 1.26% | 1,943,766 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $25.3M | 1.25% | 2,133,576 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $17.0M | 0.84% | 610,808 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $14.3M | 0.71% | 632,931 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $14.3M | 0.71% | 1,379,965 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $6.9M | 0.34% | 1,609,569 | Common | SOLE |
| G1933S101 | CASIF | CASI PHARMACEUTICALS INC | $839,170 | 0.04% | 987,259 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.